<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581034</url>
  </required_header>
  <id_info>
    <org_study_id>146/11</org_study_id>
    <nct_id>NCT01581034</nct_id>
  </id_info>
  <brief_title>Effect of PADMA 28 on Endothelial Function, Autonomic Nervous System and Biomarkers in Patients With Coronary Artery Disease</brief_title>
  <acronym>PADMA 28</acronym>
  <official_title>A Randomized, Placebo-controlled, Double-blinded Trial on the Effect of PADMA 28 on Endothelial Function, Biomarkers and the Autonomic Nervous System in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, placebo-controlled, double-blinded trial investigates the effect of a 6 week&#xD;
      intake of PADMA 28 on the endothelial function, biomarkers and the autonomic nervous systems&#xD;
      in patients with coronary artery disease. The investigators hypothesize that PADMA 28 has a&#xD;
      beneficial effect on endothelial function, arterial stiffness, the autonomic nervous systen&#xD;
      and the blood inflammatory markers in patients with coronary artery disease compared to&#xD;
      placebo treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      This randomized, placebo-controlled, double-blinded trial investigates the effect of a 6 week&#xD;
      intake of PADMA 28 on the endothelial function, biomarkers and the autonomic nervous systems&#xD;
      in patients with coronary artery disease. PADMA 28 contains 20 herbs from Tibet. The&#xD;
      endothelial function will be measured by EndoPAT 2000, the autonomic nervous system by an&#xD;
      ambulatory electrocardiography during the orthostatic reaction and the biomarkers will be&#xD;
      analyzed with taking a blood sample. The investigators hypothesize that PADMA 28 has a&#xD;
      beneficial effect on endothelial function, arterial stiffness, the autonomic nervous systen&#xD;
      and the blood inflammatory markers in patients with coronary artery disease compared to&#xD;
      placebo treatment.&#xD;
&#xD;
      Objective&#xD;
&#xD;
      To assess the effect of PADMA 28 on endothelial function, autonomic nervous system and&#xD;
      biomarkers in patients with coronary artery disease.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      80 patients with coronary artery disease will be recruited for the study. To measure&#xD;
      endothelial function, the investigators use EndoPAT 2000. The autonomic nervous system will&#xD;
      be analysed with ambulatory electrocardiography.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>At completion of the study, expected to be at 6 weeks</time_frame>
    <description>Expressed as Reactive Hyperemic Index (RHI), measured by non-invasive peripheral arterial tonometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Autonomic nervous system</measure>
    <time_frame>At completion of the study, expected to be at 6 weeks</time_frame>
    <description>Cardiac autonomic tone (expressed as frequency domain parameters of heart rate variability (HRV) &amp; measured by ECG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers in blood</measure>
    <time_frame>At completion of the study, expected to be at 6 weeks</time_frame>
    <description>Blood inflammatory and anticoagulative biomarkers, measured by fasting blood samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Padma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PADMA 28</intervention_name>
    <description>PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.</description>
    <arm_group_label>Padma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patient with coronary artery disease&#xD;
&#xD;
          -  Stable medication&#xD;
&#xD;
          -  Physically stable&#xD;
&#xD;
          -  Psychologically stable&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Willing and able to comply with all trial requirements&#xD;
&#xD;
          -  Must have completed rehabilitation program since at least 6 months and no longer than&#xD;
             5 years prior to study begin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute coronary syndrome within the last three months&#xD;
&#xD;
          -  Abnormal high hepatic enzymes&#xD;
&#xD;
          -  Renal insufficiency with compensated retention&#xD;
&#xD;
          -  Intake of medication which may affect endothelial function&#xD;
&#xD;
          -  Currently smoking&#xD;
&#xD;
          -  Current malignant diseases, which may reduce the expectancy of life&#xD;
&#xD;
          -  Chronic heart failure&#xD;
&#xD;
          -  Insulin-dependent diabetes&#xD;
&#xD;
          -  Known hypersensitivity against any ingredient of PADMA 28&#xD;
&#xD;
          -  Longterm intake of supplements&#xD;
&#xD;
          -  Serious mental health issues&#xD;
&#xD;
          -  Alcohol and/or drug abuse&#xD;
&#xD;
          -  Simultaneous participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo Saner, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of cardiovascular prevention and rehabilitation, Bern University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swiss Cardiovascular Prevention and Rehabilitation Center, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2012</study_first_posted>
  <last_update_submitted>July 31, 2013</last_update_submitted>
  <last_update_submitted_qc>July 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>biomarkers</keyword>
  <keyword>autonomic nervous system</keyword>
  <keyword>coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

